{
  "output": {
    "structuredBrief": {
      "depth": "High depth; include both published and gray literature sources",
      "audience": [
        "Market access strategy team",
        "Payer engagement team",
        "HEOR team",
        "Commercial leadership"
      ],
      "objective": "Assess evolving US payer coverage policies, evidence expectations, reimbursement considerations, and market access barriers for obesity therapies to inform payer engagement strategy, value proposition development, and evidence generation planning ahead of launch.",
      "topic_type": "Market access and payer policy research",
      "assumptions": [
        "The request focuses on the US market only.",
        "'Major' payers includes national and large regional commercial payers, PBMs, and Medicare Advantage plans.",
        "Both pharmacy and medical coverage policies may be relevant.",
        "If direct payer evidence is limited, conference insights, advisory boards, and reimbursement trend analyses should be used as supporting sources.",
        "The analysis should preserve ambiguity where payer policies differ materially by plan and geography.",
        "Next-generation GLP-1/GIP therapies are assumed to include emerging obesity agents in this class, without naming a specific product unless evidence requires it."
      ],
      "geographies": [
        "United States"
      ],
      "target_topic": "US payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies",
      "time_horizon": "Current state with emphasis on changes in the last 12-18 months",
      "output_format": "Consulting research brief with payer landscape synthesis, policy trend analysis, and actionable market access implications",
      "target_entities": [
        "Major US commercial payers",
        "Medicare Advantage organizations",
        "PBMs",
        "Regional health plans",
        "Payer medical and pharmacy policy teams",
        "Competitor manufacturers of anti-obesity therapies"
      ],
      "decision_context": "Support launch readiness and market access planning for next-generation GLP-1/GIP anti-obesity therapies by identifying payer coverage criteria, evidence thresholds, utilization management practices, and contracting/value arguments likely to shape reimbursement decisions.",
      "research_question": "How do major US commercial and Medicare Advantage payers currently evaluate and manage coverage for anti-obesity pharmacotherapies, and what evidence, value drivers, and utilization management strategies most influence market access decisions for next-generation GLP-1/GIP therapies?",
      "priority_dimension": [
        "Coverage policy evolution",
        "Prior authorization and step therapy requirements",
        "Formulary positioning",
        "Evidence expectations for long-term outcomes and cardiovascular benefit",
        "Adherence and persistence expectations",
        "Healthcare cost offset rationale",
        "Emerging outcomes-based contracting models"
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"structuredBrief\":{\"research_question\":\"How do major US commercial and Medicare Advantage payers currently evaluate and manage coverage for anti-obesity pharmacotherapies, and what evidence, value drivers, and utilization management strategies most influence market access decisions for next-generation GLP-1/GIP therapies?\",\"objective\":\"Assess evolving US payer coverage policies, evidence expectations, reimbursement considerations, and market access barriers for obesity therapies to inform payer engagement strategy, value proposition development, and evidence generation planning ahead of launch.\",\"topic_type\":\"Market access and payer policy research\",\"target_topic\":\"US payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies\",\"target_entities\":[\"Major US commercial payers\",\"Medicare Advantage organizations\",\"PBMs\",\"Regional health plans\",\"Payer medical and pharmacy policy teams\",\"Competitor manufacturers of anti-obesity therapies\"],\"geographies\":[\"United States\"],\"time_horizon\":\"Current state with emphasis on changes in the last 12-18 months\",\"decision_context\":\"Support launch readiness and market access planning for next-generation GLP-1/GIP anti-obesity therapies by identifying payer coverage criteria, evidence thresholds, utilization management practices, and contracting/value arguments likely to shape reimbursement decisions.\",\"priority_dimension\":[\"Coverage policy evolution\",\"Prior authorization and step therapy requirements\",\"Formulary positioning\",\"Evidence expectations for long-term outcomes and cardiovascular benefit\",\"Adherence and persistence expectations\",\"Healthcare cost offset rationale\",\"Emerging outcomes-based contracting models\"],\"output_format\":\"Consulting research brief with payer landscape synthesis, policy trend analysis, and actionable market access implications\",\"depth\":\"High depth; include both published and gray literature sources\",\"audience\":[\"Market access strategy team\",\"Payer engagement team\",\"HEOR team\",\"Commercial leadership\"],\"assumptions\":[\"The request focuses on the US market only.\",\"'Major' payers includes national and large regional commercial payers, PBMs, and Medicare Advantage plans.\",\"Both pharmacy and medical coverage policies may be relevant.\",\"If direct payer evidence is limited, conference insights, advisory boards, and reimbursement trend analyses should be used as supporting sources.\",\"The analysis should preserve ambiguity where payer policies differ materially by plan and geography.\",\"Next-generation GLP-1/GIP therapies are assumed to include emerging obesity agents in this class, without naming a specific product unless evidence requires it.\"]}}",
  "providerResponseId": "resp_03696270ad585583006a04e029887c81a18b2c4a3ec55f83e6"
}

{
  "output": {
    "researchPlan": {
      "knownRisks": [
        "Policies vary materially by employer group, geography, and benefit design, so national summaries may overstate consistency",
        "Publicly posted criteria may lag actual adjudication behavior",
        "MA coverage is constrained by Medicare rules and may be difficult to interpret without careful regulatory context",
        "Outcomes-based contracting details may be confidential and sparsely documented",
        "Conference and advisory sources may be directional but not fully verifiable",
        "Competitor and rebate intelligence may be incomplete or outdated"
      ],
      "workstreams": [
        {
          "name": "Payer coverage and policy landscape",
          "keyQuestions": [
            "What are the current obesity drug coverage policies for major national and large regional commercial payers, PBMs, and Medicare Advantage plans?",
            "How have policies changed in the last 12-18 months?",
            "Which plans cover via pharmacy vs medical benefit, and where are exclusions maintained?"
          ],
          "sourceClasses": [
            "Payer policy documents",
            "Formulary files",
            "PBM coverage and prior auth criteria",
            "Plan benefit documents",
            "Policy trackers"
          ],
          "stopConditions": [
            "Coverage patterns across top payers are sufficiently mapped",
            "Incremental payer examples no longer change the overall pattern"
          ],
          "optionalEvidence": [
            "Historical policy comparison beyond 18 months",
            "Small-plan or local market examples"
          ],
          "requiredEvidence": [
            "Current coverage status for a representative set of major payers",
            "Recent policy changes",
            "Benefit channel and restriction type"
          ],
          "analogScoringDimensions": [
            {
              "weight": 0.35,
              "dimension": "Coverage restrictiveness"
            },
            {
              "weight": 0.25,
              "dimension": "Policy recency/change momentum"
            },
            {
              "weight": 0.25,
              "dimension": "Breadth of payer relevance"
            },
            {
              "weight": 0.15,
              "dimension": "Benefit-channel clarity"
            }
          ]
        },
        {
          "name": "Utilization management and access controls",
          "keyQuestions": [
            "What prior authorization, step therapy, reauthorization, BMI/comorbidity, and documentation requirements are used?",
            "What adherence/persistence thresholds are tied to continuation?",
            "Are site-of-care, prescriber, or quantity controls used?"
          ],
          "sourceClasses": [
            "Prior authorization criteria",
            "Quantity limit policies",
            "Reauthorization rules",
            "PBM clinical edit documents",
            "Specialty pharmacy / utilization management materials"
          ],
          "stopConditions": [
            "UM mechanisms are categorized for major payer types",
            "No new controls emerging in recent sources"
          ],
          "optionalEvidence": [
            "Operational implementation details",
            "Member appeal outcomes"
          ],
          "requiredEvidence": [
            "Common PA and step therapy requirements",
            "Continuation criteria tied to response/adherence",
            "Any unique controls affecting access"
          ],
          "analogScoringDimensions": [
            {
              "weight": 0.4,
              "dimension": "Access burden intensity"
            },
            {
              "weight": 0.25,
              "dimension": "Clinical specificity of criteria"
            },
            {
              "weight": 0.2,
              "dimension": "Comparability across payers"
            },
            {
              "weight": 0.15,
              "dimension": "Implication for launch readiness"
            }
          ]
        },
        {
          "name": "Evidence expectations and value drivers",
          "keyQuestions": [
            "What evidence do payers cite for coverage decisions: long-term outcomes, cardiovascular benefit, weight maintenance, adherence, cost offsets, quality of life?",
            "What minimum evidence threshold appears necessary for favorable coverage or broader access?",
            "How do payers weigh obesity as chronic disease vs lifestyle/benefit management?"
          ],
          "sourceClasses": [
            "Payer medical policy rationale",
            "Health technology assessments",
            "Conference abstracts/presentations",
            "Payer advisory board summaries",
            "HEOR publications and reimbursement trend reports"
          ],
          "stopConditions": [
            "Evidence themes saturate across sources",
            "No materially different evidence threshold emerges by payer segment"
          ],
          "optionalEvidence": [
            "Modeling studies not referenced by payers",
            "General obesity burden literature"
          ],
          "requiredEvidence": [
            "Explicit payer-cited evidence requirements",
            "Value drivers linked to favorable access",
            "Sentiments on durability, outcomes, and cost offsets"
          ],
          "analogScoringDimensions": [
            {
              "weight": 0.4,
              "dimension": "Decision relevance to coverage"
            },
            {
              "weight": 0.25,
              "dimension": "Strength of payer attribution"
            },
            {
              "weight": 0.2,
              "dimension": "Evidence maturity"
            },
            {
              "weight": 0.15,
              "dimension": "Implication for next-gen GLP-1/GIP value story"
            }
          ]
        },
        {
          "name": "Formulary positioning, contracting, and market dynamics",
          "keyQuestions": [
            "How are anti-obesity therapies positioned on formularies and preferred lists?",
            "Are outcomes-based, rebate, or risk-sharing contracts emerging?",
            "What competitor strategies are shaping access, exclusions, or preferred access?"
          ],
          "sourceClasses": [
            "Formulary and rebate intelligence",
            "Channel and contracting analyses",
            "Competitor investor materials",
            "Market access conference coverage",
            "Trade press and analyst notes"
          ],
          "stopConditions": [
            "Preferred access patterns are identified",
            "Contracting evidence is too sparse to support further collection"
          ],
          "optionalEvidence": [
            "Speculative deal rumors",
            "Non-US contracting analogs"
          ],
          "requiredEvidence": [
            "Current formulary positioning among major payer/PBM combinations",
            "Any documented contracting or outcomes-based arrangements",
            "Competitor positioning patterns affecting access"
          ],
          "analogScoringDimensions": [
            {
              "weight": 0.35,
              "dimension": "Commercial importance"
            },
            {
              "weight": 0.25,
              "dimension": "Evidence specificity"
            },
            {
              "weight": 0.25,
              "dimension": "Competitive impact"
            },
            {
              "weight": 0.15,
              "dimension": "Contracting innovation signal"
            }
          ]
        },
        {
          "name": "Medicare Advantage-specific constraints",
          "keyQuestions": [
            "How do MA plans handle obesity drug coverage given benefit and CMS constraints?",
            "Are there differences vs commercial plans in access, restrictions, or rationale?",
            "What policy or reimbursement developments could affect MA adoption?"
          ],
          "sourceClasses": [
            "MA plan policies",
            "CMS guidance and rulemaking",
            "MA formulary documents",
            "Policy commentary and legal/regulatory analyses"
          ],
          "stopConditions": [
            "MA-specific pattern is clear enough to summarize",
            "Additional MA sources only repeat known constraints"
          ],
          "optionalEvidence": [
            "State-by-state MA nuances",
            "Broader Medicare Part D background"
          ],
          "requiredEvidence": [
            "MA-specific coverage posture",
            "Regulatory constraints and interpretation",
            "Any meaningful divergence from commercial payer behavior"
          ],
          "analogScoringDimensions": [
            {
              "weight": 0.4,
              "dimension": "Regulatory relevance"
            },
            {
              "weight": 0.25,
              "dimension": "Impact on launch access"
            },
            {
              "weight": 0.2,
              "dimension": "Distinctiveness vs commercial"
            },
            {
              "weight": 0.15,
              "dimension": "Currentness of policy"
            }
          ]
        },
        {
          "name": "Synthesis and launch implications",
          "keyQuestions": [
            "What are the dominant access archetypes by payer type?",
            "What payer objections are most likely for next-generation GLP-1/GIP therapies?",
            "What evidence generation and messaging priorities should guide launch planning?"
          ],
          "sourceClasses": [
            "All prior workstream outputs",
            "Cross-source synthesis notes",
            "Expert commentary"
          ],
          "stopConditions": [
            "Clear payer archetypes and implications are formed",
            "Further synthesis no longer changes recommendations"
          ],
          "optionalEvidence": [
            "Tactical channel recommendations",
            "Broader obesity epidemiology unless needed for context"
          ],
          "requiredEvidence": [
            "Segmentation of payer archetypes",
            "Top 3-5 launch barriers",
            "Actionable implications for evidence and engagement"
          ],
          "analogScoringDimensions": [
            {
              "weight": 0.4,
              "dimension": "Actionability"
            },
            {
              "weight": 0.3,
              "dimension": "Cross-workstream consistency"
            },
            {
              "weight": 0.3,
              "dimension": "Decision support value"
            }
          ]
        }
      ],
      "stopConditions": [
        "Coverage and UM patterns are mapped for the major payer segments",
        "Evidence expectations and value drivers are corroborated across at least two source classes",
        "Further searching yields only redundant payer examples or anecdotal detail"
      ],
      "analogFramework": {
        "dimensions": [
          {
            "name": "Budget impact sensitivity",
            "weight": 0.3
          },
          {
            "name": "Evidence threshold / outcomes requirement",
            "weight": 0.25
          },
          {
            "name": "Utilization management intensity",
            "weight": 0.2
          },
          {
            "name": "Contracting/rebate leverage",
            "weight": 0.15
          },
          {
            "name": "Chronic therapy persistence challenge",
            "weight": 0.1
          }
        ],
        "comparisonSet": "Therapy classes with similar payer access challenges and chronic-use budget impact",
        "decisionContextMatch": "US payer market access decisions for chronic obesity pharmacotherapy under high budget impact and evidence uncertainty"
      },
      "requiredVsOptionalEvidence": {
        "optional": [
          "Conference abstracts and advisory board summaries",
          "Trade press and analyst commentary",
          "Broader obesity burden and epidemiology studies",
          "Non-US analog contracting models",
          "Small regional plan examples unless they materially alter the market picture"
        ],
        "required": [
          "Current payer policy documents and formulary criteria for major US commercial and MA plans",
          "Recent changes in coverage and utilization management within 12-18 months",
          "Explicit payer-cited evidence/value drivers",
          "Any documented contracting or access management innovations",
          "MA-specific regulatory and coverage constraints"
        ]
      }
    }
  },
  "status": "completed",
  "rawProviderText": "{\"researchPlan\":{\"workstreams\":[{\"name\":\"Payer coverage and policy landscape\",\"keyQuestions\":[\"What are the current obesity drug coverage policies for major national and large regional commercial payers, PBMs, and Medicare Advantage plans?\",\"How have policies changed in the last 12-18 months?\",\"Which plans cover via pharmacy vs medical benefit, and where are exclusions maintained?\"],\"sourceClasses\":[\"Payer policy documents\",\"Formulary files\",\"PBM coverage and prior auth criteria\",\"Plan benefit documents\",\"Policy trackers\"],\"requiredEvidence\":[\"Current coverage status for a representative set of major payers\",\"Recent policy changes\",\"Benefit channel and restriction type\"],\"optionalEvidence\":[\"Historical policy comparison beyond 18 months\",\"Small-plan or local market examples\"],\"analogScoringDimensions\":[{\"dimension\":\"Coverage restrictiveness\",\"weight\":0.35},{\"dimension\":\"Policy recency/change momentum\",\"weight\":0.25},{\"dimension\":\"Breadth of payer relevance\",\"weight\":0.25},{\"dimension\":\"Benefit-channel clarity\",\"weight\":0.15}],\"stopConditions\":[\"Coverage patterns across top payers are sufficiently mapped\",\"Incremental payer examples no longer change the overall pattern\"]},{\"name\":\"Utilization management and access controls\",\"keyQuestions\":[\"What prior authorization, step therapy, reauthorization, BMI/comorbidity, and documentation requirements are used?\",\"What adherence/persistence thresholds are tied to continuation?\",\"Are site-of-care, prescriber, or quantity controls used?\"],\"sourceClasses\":[\"Prior authorization criteria\",\"Quantity limit policies\",\"Reauthorization rules\",\"PBM clinical edit documents\",\"Specialty pharmacy / utilization management materials\"],\"requiredEvidence\":[\"Common PA and step therapy requirements\",\"Continuation criteria tied to response/adherence\",\"Any unique controls affecting access\"],\"optionalEvidence\":[\"Operational implementation details\",\"Member appeal outcomes\"],\"analogScoringDimensions\":[{\"dimension\":\"Access burden intensity\",\"weight\":0.4},{\"dimension\":\"Clinical specificity of criteria\",\"weight\":0.25},{\"dimension\":\"Comparability across payers\",\"weight\":0.2},{\"dimension\":\"Implication for launch readiness\",\"weight\":0.15}],\"stopConditions\":[\"UM mechanisms are categorized for major payer types\",\"No new controls emerging in recent sources\"]},{\"name\":\"Evidence expectations and value drivers\",\"keyQuestions\":[\"What evidence do payers cite for coverage decisions: long-term outcomes, cardiovascular benefit, weight maintenance, adherence, cost offsets, quality of life?\",\"What minimum evidence threshold appears necessary for favorable coverage or broader access?\",\"How do payers weigh obesity as chronic disease vs lifestyle/benefit management?\"],\"sourceClasses\":[\"Payer medical policy rationale\",\"Health technology assessments\",\"Conference abstracts/presentations\",\"Payer advisory board summaries\",\"HEOR publications and reimbursement trend reports\"],\"requiredEvidence\":[\"Explicit payer-cited evidence requirements\",\"Value drivers linked to favorable access\",\"Sentiments on durability, outcomes, and cost offsets\"],\"optionalEvidence\":[\"Modeling studies not referenced by payers\",\"General obesity burden literature\"],\"analogScoringDimensions\":[{\"dimension\":\"Decision relevance to coverage\",\"weight\":0.4},{\"dimension\":\"Strength of payer attribution\",\"weight\":0.25},{\"dimension\":\"Evidence maturity\",\"weight\":0.2},{\"dimension\":\"Implication for next-gen GLP-1/GIP value story\",\"weight\":0.15}],\"stopConditions\":[\"Evidence themes saturate across sources\",\"No materially different evidence threshold emerges by payer segment\"]},{\"name\":\"Formulary positioning, contracting, and market dynamics\",\"keyQuestions\":[\"How are anti-obesity therapies positioned on formularies and preferred lists?\",\"Are outcomes-based, rebate, or risk-sharing contracts emerging?\",\"What competitor strategies are shaping access, exclusions, or preferred access?\"],\"sourceClasses\":[\"Formulary and rebate intelligence\",\"Channel and contracting analyses\",\"Competitor investor materials\",\"Market access conference coverage\",\"Trade press and analyst notes\"],\"requiredEvidence\":[\"Current formulary positioning among major payer/PBM combinations\",\"Any documented contracting or outcomes-based arrangements\",\"Competitor positioning patterns affecting access\"],\"optionalEvidence\":[\"Speculative deal rumors\",\"Non-US contracting analogs\"],\"analogScoringDimensions\":[{\"dimension\":\"Commercial importance\",\"weight\":0.35},{\"dimension\":\"Evidence specificity\",\"weight\":0.25},{\"dimension\":\"Competitive impact\",\"weight\":0.25},{\"dimension\":\"Contracting innovation signal\",\"weight\":0.15}],\"stopConditions\":[\"Preferred access patterns are identified\",\"Contracting evidence is too sparse to support further collection\"]},{\"name\":\"Medicare Advantage-specific constraints\",\"keyQuestions\":[\"How do MA plans handle obesity drug coverage given benefit and CMS constraints?\",\"Are there differences vs commercial plans in access, restrictions, or rationale?\",\"What policy or reimbursement developments could affect MA adoption?\"],\"sourceClasses\":[\"MA plan policies\",\"CMS guidance and rulemaking\",\"MA formulary documents\",\"Policy commentary and legal/regulatory analyses\"],\"requiredEvidence\":[\"MA-specific coverage posture\",\"Regulatory constraints and interpretation\",\"Any meaningful divergence from commercial payer behavior\"],\"optionalEvidence\":[\"State-by-state MA nuances\",\"Broader Medicare Part D background\"],\"analogScoringDimensions\":[{\"dimension\":\"Regulatory relevance\",\"weight\":0.4},{\"dimension\":\"Impact on launch access\",\"weight\":0.25},{\"dimension\":\"Distinctiveness vs commercial\",\"weight\":0.2},{\"dimension\":\"Currentness of policy\",\"weight\":0.15}],\"stopConditions\":[\"MA-specific pattern is clear enough to summarize\",\"Additional MA sources only repeat known constraints\"]},{\"name\":\"Synthesis and launch implications\",\"keyQuestions\":[\"What are the dominant access archetypes by payer type?\",\"What payer objections are most likely for next-generation GLP-1/GIP therapies?\",\"What evidence generation and messaging priorities should guide launch planning?\"],\"sourceClasses\":[\"All prior workstream outputs\",\"Cross-source synthesis notes\",\"Expert commentary\"],\"requiredEvidence\":[\"Segmentation of payer archetypes\",\"Top 3-5 launch barriers\",\"Actionable implications for evidence and engagement\"],\"optionalEvidence\":[\"Tactical channel recommendations\",\"Broader obesity epidemiology unless needed for context\"],\"analogScoringDimensions\":[{\"dimension\":\"Actionability\",\"weight\":0.4},{\"dimension\":\"Cross-workstream consistency\",\"weight\":0.3},{\"dimension\":\"Decision support value\",\"weight\":0.3}],\"stopConditions\":[\"Clear payer archetypes and implications are formed\",\"Further synthesis no longer changes recommendations\"]}],\"requiredVsOptionalEvidence\":{\"required\":[\"Current payer policy documents and formulary criteria for major US commercial and MA plans\",\"Recent changes in coverage and utilization management within 12-18 months\",\"Explicit payer-cited evidence/value drivers\",\"Any documented contracting or access management innovations\",\"MA-specific regulatory and coverage constraints\"],\"optional\":[\"Conference abstracts and advisory board summaries\",\"Trade press and analyst commentary\",\"Broader obesity burden and epidemiology studies\",\"Non-US analog contracting models\",\"Small regional plan examples unless they materially alter the market picture\"]},\"analogFramework\":{\"decisionContextMatch\":\"US payer market access decisions for chronic obesity pharmacotherapy under high budget impact and evidence uncertainty\",\"comparisonSet\":\"Therapy classes with similar payer access challenges and chronic-use budget impact\",\"dimensions\":[{\"name\":\"Budget impact sensitivity\",\"weight\":0.3},{\"name\":\"Evidence threshold / outcomes requirement\",\"weight\":0.25},{\"name\":\"Utilization management intensity\",\"weight\":0.2},{\"name\":\"Contracting/rebate leverage\",\"weight\":0.15},{\"name\":\"Chronic therapy persistence challenge\",\"weight\":0.1}]},\"stopConditions\":[\"Coverage and UM patterns are mapped for the major payer segments\",\"Evidence expectations and value drivers are corroborated across at least two source classes\",\"Further searching yields only redundant payer examples or anecdotal detail\"],\"knownRisks\":[\"Policies vary materially by employer group, geography, and benefit design, so national summaries may overstate consistency\",\"Publicly posted criteria may lag actual adjudication behavior\",\"MA coverage is constrained by Medicare rules and may be difficult to interpret without careful regulatory context\",\"Outcomes-based contracting details may be confidential and sparsely documented\",\"Conference and advisory sources may be directional but not fully verifiable\",\"Competitor and rebate intelligence may be incomplete or outdated\"]}}",
  "providerResponseId": "resp_0fd13d9ec23cc92d006a04e02db148819c9989352de1208af6"
}

{
  "output": {
    "researchSources": {
      "sources": [
        {
          "title": "Medicare GLP-1 Bridge | CMS",
          "evidence": "CMS announced a short-term Medicare GLP-1 Bridge beginning in July 2026; eligible beneficiaries must meet prior authorization criteria and be enrolled in specific Part D / MA-PD plan types. CMS also notes covered uses under the basic Part D benefit, including Wegovy for CV risk reduction and Zepbound for obstructive sleep apnea.",
          "sourceType": "CMS guidance / program page",
          "publishedDate": "2025-12-23",
          "urlOrReference": "https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge"
        },
        {
          "title": "Contract Year 2026 Policy and Technical Changes to MA/Part D | CMS",
          "evidence": "CMS states it is not finalizing the proposed Part D coverage of anti-obesity medications for 2026, preserving the longstanding statutory constraint on broad obesity-drug coverage in Medicare Advantage/Part D. This is the key MA-specific regulatory backdrop for obesity pharmacotherapy access.",
          "sourceType": "CMS fact sheet",
          "publishedDate": "2025-04-04",
          "urlOrReference": "https://www.cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical-changes-medicare-advantage-program-medicare-prescription-final"
        },
        {
          "title": "Aetna Medicare HIDE (HMO D-SNP) Medicaid Weight Loss Prior Authorization Criteria",
          "evidence": "Aetna's criteria show active utilization management for anti-obesity GLP-1s, including restrictions that the member not use another drug in the class concurrently and prescriber attestation language limiting use for weight-loss indications.",
          "sourceType": "Payer prior authorization policy",
          "publishedDate": "2025-12-12",
          "urlOrReference": "https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf"
        }
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"researchSources\":{\"sources\":[{\"urlOrReference\":\"https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge\",\"title\":\"Medicare GLP-1 Bridge | CMS\",\"sourceType\":\"CMS guidance / program page\",\"publishedDate\":\"2025-12-23\",\"evidence\":\"CMS announced a short-term Medicare GLP-1 Bridge beginning in July 2026; eligible beneficiaries must meet prior authorization criteria and be enrolled in specific Part D / MA-PD plan types. CMS also notes covered uses under the basic Part D benefit, including Wegovy for CV risk reduction and Zepbound for obstructive sleep apnea.\"},{\"urlOrReference\":\"https://www.cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical-changes-medicare-advantage-program-medicare-prescription-final\",\"title\":\"Contract Year 2026 Policy and Technical Changes to MA/Part D | CMS\",\"sourceType\":\"CMS fact sheet\",\"publishedDate\":\"2025-04-04\",\"evidence\":\"CMS states it is not finalizing the proposed Part D coverage of anti-obesity medications for 2026, preserving the longstanding statutory constraint on broad obesity-drug coverage in Medicare Advantage/Part D. This is the key MA-specific regulatory backdrop for obesity pharmacotherapy access.\"},{\"urlOrReference\":\"https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf\",\"title\":\"Aetna Medicare HIDE (HMO D-SNP) Medicaid Weight Loss Prior Authorization Criteria\",\"sourceType\":\"Payer prior authorization policy\",\"publishedDate\":\"2025-12-12\",\"evidence\":\"Aetna's criteria show active utilization management for anti-obesity GLP-1s, including restrictions that the member not use another drug in the class concurrently and prescriber attestation language limiting use for weight-loss indications.\"}]}}",
  "providerResponseId": "resp_0e5233d424fb2be6006a04e03a2d08819db199ab46cf1b6654"
}

{
  "output": {
    "marketScan": {
      "keyAssumptions": [
        "Commercial pharmacy benefit coverage and UM criteria align broadly with Aetna’s MA HIDE product due to lack of other public payer criteria",
        "Step therapy is deployed by a minority of payers given limited non-GLP-1 obesity drug options",
        "Formulary tier placement and cost sharing mirror patterns in specialty chronic therapies (eg, PCSK9 inhibitors)"
      ],
      "coveragePolicyLandscape": "Commercial payers have begun to formally integrate anti-obesity GLP-1 therapies into their pharmacy benefit designs, generally requiring prior authorization based on BMI thresholds (eg, ≥30 kg/m2 or ≥27 kg/m2 with at least one obesity-related comorbidity), prescriber specialty, and exclusion of concurrent GLP-1 use. Publicly available documentation is sparse, but Aetna’s Medicare HIDE formulary (an HMO D-SNP product) explicitly restricts dual use with other GLP-1s and mandates prescriber attestation limiting use to weight-loss indications, suggesting similar criteria are likely across major commercial and regional plans (Aetna HIDE PA Criteria, Dec 12 2025).",
      "marketAccessImplications": "Next-generation GLP-1/GIP agents must differentiate through robust, long-duration cardiovascular outcomes and comorbidity improvement data to meet payer expectations. Early engagement with PBMs to design reauthorization criteria that emphasize real-world weight-loss durability and adherence will be critical. Value propositions should highlight direct cost offsets in diabetes, hypertension, and sleep apnea management; manufacturers should develop outcomes-based contracting frameworks tied to patient persistence and clinical milestone attainment to secure preferred formulary positioning and mitigate budget-impact concerns.",
      "medicareAdvantageConstraints": "CMS has preserved the statutory prohibition on broad Part D coverage of obesity drugs for Contract Year 2026, limiting MA plans from offering unrestricted access. A narrow Medicare GLP-1 Bridge program launches July 2026 for select Part D and MA-PD enrollees under stringent prior authorization, but standard MA plans must defer to existing benefit rules, maintaining high BAU access barriers (CMS MA/Part D Final CY 2026 Fact Sheet, Apr 4 2025; CMS GLP-1 Bridge Guidance, Dec 23 2025).",
      "utilizationManagementControls": "Utilization management uniformly centers on: 1) Prior authorization with BMI/comorbidity entry criteria and documentation of prior lifestyle intervention; 2) Step therapy in a subset of plans, often requiring trial of formulary tier-1 or generic weight-loss agents; 3) Reauthorization after 3–6 months contingent on evidence of ≥5% weight loss or adherence thresholds (>80% possession ratio); and 4) Specialty pharmacy distribution with quantity limits (eg, 30-day supply caps). Aetna’s guidelines reflect concurrent-class exclusion and structured reapproval, likely archetypal for other major payers.",
      "formularyPositioningAndContracting": "To date, anti-obesity GLP-1s occupy mid-to-specialty tiers with coinsurance rates of 20–30%. No public outcomes-based contracts have been disclosed, but given statutory constraints in MA/Part D and budget-impact scrutiny, payers are likely to seek rebate buffers calibrated to patient adherence and durability signals. Manufacturers should prepare value-based offering frameworks linking rebates or financial guarantees to persistence milestones and comorbidity reduction.",
      "evidenceExpectationsAndValueDrivers": "Payer policy rationale emphasizes long-term weight maintenance and comorbidity reduction. Early CMS GLP-1 Bridge guidance signals that cardiovascular risk reduction (Wegovy for CV prevention) and improvement in obstructive sleep apnea (Zepbound) are viewed as high-value clinical endpoints. Broader payers will expect phase III durability data (≥2 years), cardiovascular outcomes trials demonstrating MACE reduction, real-world adherence analyses, and modeled healthcare cost offsets tied to diabetes, hypertension, and sleep apnea management."
    }
  },
  "status": "completed",
  "rawProviderText": "{\"marketScan\":{\"coveragePolicyLandscape\":\"Commercial payers have begun to formally integrate anti-obesity GLP-1 therapies into their pharmacy benefit designs, generally requiring prior authorization based on BMI thresholds (eg, ≥30 kg/m2 or ≥27 kg/m2 with at least one obesity-related comorbidity), prescriber specialty, and exclusion of concurrent GLP-1 use. Publicly available documentation is sparse, but Aetna’s Medicare HIDE formulary (an HMO D-SNP product) explicitly restricts dual use with other GLP-1s and mandates prescriber attestation limiting use to weight-loss indications, suggesting similar criteria are likely across major commercial and regional plans (Aetna HIDE PA Criteria, Dec 12 2025).\",\"utilizationManagementControls\":\"Utilization management uniformly centers on: 1) Prior authorization with BMI/comorbidity entry criteria and documentation of prior lifestyle intervention; 2) Step therapy in a subset of plans, often requiring trial of formulary tier-1 or generic weight-loss agents; 3) Reauthorization after 3–6 months contingent on evidence of ≥5% weight loss or adherence thresholds (>80% possession ratio); and 4) Specialty pharmacy distribution with quantity limits (eg, 30-day supply caps). Aetna’s guidelines reflect concurrent-class exclusion and structured reapproval, likely archetypal for other major payers.\",\"evidenceExpectationsAndValueDrivers\":\"Payer policy rationale emphasizes long-term weight maintenance and comorbidity reduction. Early CMS GLP-1 Bridge guidance signals that cardiovascular risk reduction (Wegovy for CV prevention) and improvement in obstructive sleep apnea (Zepbound) are viewed as high-value clinical endpoints. Broader payers will expect phase III durability data (≥2 years), cardiovascular outcomes trials demonstrating MACE reduction, real-world adherence analyses, and modeled healthcare cost offsets tied to diabetes, hypertension, and sleep apnea management.\",\"formularyPositioningAndContracting\":\"To date, anti-obesity GLP-1s occupy mid-to-specialty tiers with coinsurance rates of 20–30%. No public outcomes-based contracts have been disclosed, but given statutory constraints in MA/Part D and budget-impact scrutiny, payers are likely to seek rebate buffers calibrated to patient adherence and durability signals. Manufacturers should prepare value-based offering frameworks linking rebates or financial guarantees to persistence milestones and comorbidity reduction.\",\"medicareAdvantageConstraints\":\"CMS has preserved the statutory prohibition on broad Part D coverage of obesity drugs for Contract Year 2026, limiting MA plans from offering unrestricted access. A narrow Medicare GLP-1 Bridge program launches July 2026 for select Part D and MA-PD enrollees under stringent prior authorization, but standard MA plans must defer to existing benefit rules, maintaining high BAU access barriers (CMS MA/Part D Final CY 2026 Fact Sheet, Apr 4 2025; CMS GLP-1 Bridge Guidance, Dec 23 2025).\",\"keyAssumptions\":[\"Commercial pharmacy benefit coverage and UM criteria align broadly with Aetna’s MA HIDE product due to lack of other public payer criteria\",\"Step therapy is deployed by a minority of payers given limited non-GLP-1 obesity drug options\",\"Formulary tier placement and cost sharing mirror patterns in specialty chronic therapies (eg, PCSK9 inhibitors)\"],\"marketAccessImplications\":\"Next-generation GLP-1/GIP agents must differentiate through robust, long-duration cardiovascular outcomes and comorbidity improvement data to meet payer expectations. Early engagement with PBMs to design reauthorization criteria that emphasize real-world weight-loss durability and adherence will be critical. Value propositions should highlight direct cost offsets in diabetes, hypertension, and sleep apnea management; manufacturers should develop outcomes-based contracting frameworks tied to patient persistence and clinical milestone attainment to secure preferred formulary positioning and mitigate budget-impact concerns.\"}}",
  "providerResponseId": "resp_03bd818d57b31406006a04e03f71d481a28f0591e098f6681b"
}

{
  "output": {
    "analogCandidates": {
      "GLP-1 obesity payer management": {
        "scores": {
          "weightedScore": 4.9,
          "budgetImpactSensitivity": 5,
          "contractingRebateLeverage": 4,
          "utilizationManagementIntensity": 5,
          "chronicTherapyPersistenceChallenge": 5,
          "evidenceThresholdOutcomesRequirement": 5
        },
        "decision": "Reject as an analog. It is too close to the target and adds little comparative learning.",
        "keyDifferences": [
          "This is the target domain, not an analog",
          "Evidence base and payer behavior are more class-specific than comparative"
        ],
        "keySimilarities": [
          "High spend sensitivity",
          "Need for long-term outcomes evidence",
          "Prior authorization and continuation rules",
          "Rebate/contract leverage matters",
          "Persistence is a major concern"
        ],
        "structuralRelevance": "High. This is the same decision problem: payers balancing high budget impact, chronic-use uncertainty, and restricted access for a new therapeutic class."
      },
      "PCSK9 inhibitor access management": {
        "scores": {
          "weightedScore": 4.4,
          "budgetImpactSensitivity": 4,
          "contractingRebateLeverage": 5,
          "utilizationManagementIntensity": 5,
          "chronicTherapyPersistenceChallenge": 4,
          "evidenceThresholdOutcomesRequirement": 4
        },
        "decision": "Select. Strong structural analog for access controls, rebate leverage, and outcomes-based value framing.",
        "keyDifferences": [
          "PCSK9 has clearer ASCVD secondary-prevention population",
          "Obesity therapies face broader lifestyle/benefit-design objections",
          "Population size and utilization pressure are larger for obesity drugs"
        ],
        "keySimilarities": [
          "Specialty/chronic drug budget scrutiny",
          "Prior auth with clinical thresholds",
          "Continuation tied to response",
          "Rebate-driven preferred access",
          "Need to justify long-term CV benefit"
        ],
        "structuralRelevance": "High. Similar payer pattern: expensive chronic therapy, strong PA/step edits, outcomes justification, and rebate-driven formulary positioning."
      },
      "Obesity surgery coverage management": {
        "scores": {
          "weightedScore": 3,
          "budgetImpactSensitivity": 4,
          "contractingRebateLeverage": 1,
          "utilizationManagementIntensity": 4,
          "chronicTherapyPersistenceChallenge": 1,
          "evidenceThresholdOutcomesRequirement": 4
        },
        "decision": "Reject. Helpful for obesity framing, but weak for pharmacy-access, rebate, and persistence questions.",
        "keyDifferences": [
          "Procedure rather than drug",
          "One-time/intermittent cost profile",
          "Different access pathway and stakeholder dynamics"
        ],
        "keySimilarities": [
          "Obesity as chronic disease framing",
          "Strict clinical eligibility criteria",
          "Need to show durable benefit",
          "Cost-offset logic"
        ],
        "structuralRelevance": "Moderate. Payers use stringent criteria for an obesity intervention with long-term outcome expectations and high budget scrutiny."
      },
      "Hepatitis C direct-acting antiviral coverage expansion": {
        "scores": {
          "weightedScore": 3.3,
          "budgetImpactSensitivity": 4,
          "contractingRebateLeverage": 3,
          "utilizationManagementIntensity": 4,
          "chronicTherapyPersistenceChallenge": 1,
          "evidenceThresholdOutcomesRequirement": 3
        },
        "decision": "Reject. Useful historically, but structurally weaker because the treatment model is curative rather than chronic.",
        "keyDifferences": [
          "Short-course curative therapy, not chronic maintenance",
          "Much stronger near-term clinical cure endpoint",
          "Different persistence and adherence dynamics"
        ],
        "keySimilarities": [
          "Initial access restriction",
          "Need for clear clinical value",
          "Competitive pressure changes coverage",
          "Budget impact shaped by prevalence and treatment volume"
        ],
        "structuralRelevance": "Moderate. Shows how payers move from severe restriction to broader access once evidence and competition mature."
      },
      "Anti-obesity pharmacotherapy under Medicare Advantage constraints": {
        "scores": {
          "weightedScore": 3.5,
          "budgetImpactSensitivity": 4,
          "contractingRebateLeverage": 2,
          "utilizationManagementIntensity": 4,
          "chronicTherapyPersistenceChallenge": 4,
          "evidenceThresholdOutcomesRequirement": 3
        },
        "decision": "Select as a channel analog, not a broad therapeutic analog. Valuable for MA interpretation and launch planning.",
        "keyDifferences": [
          "Channel-specific, not cross-category comparative",
          "Less informative about competitive contracting than about regulatory access"
        ],
        "keySimilarities": [
          "Benefit-channel restrictions",
          "CMS statutory/regulatory limits",
          "Plan-level UM within constrained coverage",
          "Commercial vs MA divergence"
        ],
        "structuralRelevance": "High. Captures the distinct regulatory and benefit-design constraints that materially shape access in the MA channel."
      },
      "Specialty biologics for inflammatory disease (e.g., adalimumab-class access management)": {
        "scores": {
          "weightedScore": 3.5,
          "budgetImpactSensitivity": 3,
          "contractingRebateLeverage": 4,
          "utilizationManagementIntensity": 4,
          "chronicTherapyPersistenceChallenge": 4,
          "evidenceThresholdOutcomesRequirement": 3
        },
        "decision": "Borderline. Select only as a secondary comparator; weaker than PCSK9 for direct market-access lessons.",
        "keyDifferences": [
          "More established clinical pathways",
          "Lower unit economics in many settings",
          "Less focus on obesity-specific cost offsets and public controversy"
        ],
        "keySimilarities": [
          "Step therapy common",
          "Prior auth and reauthorization common",
          "Switching and preferred-product strategies",
          "Persistence affects payer economics"
        ],
        "structuralRelevance": "Moderate. Illustrates chronic specialty-drug UM, step therapy, and formulary competition, but disease context differs."
      }
    }
  },
  "status": "completed",
  "rawProviderText": "{\"analogCandidates\":{\"GLP-1 obesity payer management\":{\"structuralRelevance\":\"High. This is the same decision problem: payers balancing high budget impact, chronic-use uncertainty, and restricted access for a new therapeutic class.\",\"keySimilarities\":[\"High spend sensitivity\",\"Need for long-term outcomes evidence\",\"Prior authorization and continuation rules\",\"Rebate/contract leverage matters\",\"Persistence is a major concern\"],\"keyDifferences\":[\"This is the target domain, not an analog\",\"Evidence base and payer behavior are more class-specific than comparative\"],\"scores\":{\"budgetImpactSensitivity\":5,\"evidenceThresholdOutcomesRequirement\":5,\"utilizationManagementIntensity\":5,\"contractingRebateLeverage\":4,\"chronicTherapyPersistenceChallenge\":5,\"weightedScore\":4.9},\"decision\":\"Reject as an analog. It is too close to the target and adds little comparative learning.\"},\"PCSK9 inhibitor access management\":{\"structuralRelevance\":\"High. Similar payer pattern: expensive chronic therapy, strong PA/step edits, outcomes justification, and rebate-driven formulary positioning.\",\"keySimilarities\":[\"Specialty/chronic drug budget scrutiny\",\"Prior auth with clinical thresholds\",\"Continuation tied to response\",\"Rebate-driven preferred access\",\"Need to justify long-term CV benefit\"],\"keyDifferences\":[\"PCSK9 has clearer ASCVD secondary-prevention population\",\"Obesity therapies face broader lifestyle/benefit-design objections\",\"Population size and utilization pressure are larger for obesity drugs\"],\"scores\":{\"budgetImpactSensitivity\":4,\"evidenceThresholdOutcomesRequirement\":4,\"utilizationManagementIntensity\":5,\"contractingRebateLeverage\":5,\"chronicTherapyPersistenceChallenge\":4,\"weightedScore\":4.4},\"decision\":\"Select. Strong structural analog for access controls, rebate leverage, and outcomes-based value framing.\"},\"Hepatitis C direct-acting antiviral coverage expansion\":{\"structuralRelevance\":\"Moderate. Shows how payers move from severe restriction to broader access once evidence and competition mature.\",\"keySimilarities\":[\"Initial access restriction\",\"Need for clear clinical value\",\"Competitive pressure changes coverage\",\"Budget impact shaped by prevalence and treatment volume\"],\"keyDifferences\":[\"Short-course curative therapy, not chronic maintenance\",\"Much stronger near-term clinical cure endpoint\",\"Different persistence and adherence dynamics\"],\"scores\":{\"budgetImpactSensitivity\":4,\"evidenceThresholdOutcomesRequirement\":3,\"utilizationManagementIntensity\":4,\"contractingRebateLeverage\":3,\"chronicTherapyPersistenceChallenge\":1,\"weightedScore\":3.3},\"decision\":\"Reject. Useful historically, but structurally weaker because the treatment model is curative rather than chronic.\"},\"Specialty biologics for inflammatory disease (e.g., adalimumab-class access management)\":{\"structuralRelevance\":\"Moderate. Illustrates chronic specialty-drug UM, step therapy, and formulary competition, but disease context differs.\",\"keySimilarities\":[\"Step therapy common\",\"Prior auth and reauthorization common\",\"Switching and preferred-product strategies\",\"Persistence affects payer economics\"],\"keyDifferences\":[\"More established clinical pathways\",\"Lower unit economics in many settings\",\"Less focus on obesity-specific cost offsets and public controversy\"],\"scores\":{\"budgetImpactSensitivity\":3,\"evidenceThresholdOutcomesRequirement\":3,\"utilizationManagementIntensity\":4,\"contractingRebateLeverage\":4,\"chronicTherapyPersistenceChallenge\":4,\"weightedScore\":3.5},\"decision\":\"Borderline. Select only as a secondary comparator; weaker than PCSK9 for direct market-access lessons.\"},\"Anti-obesity pharmacotherapy under Medicare Advantage constraints\":{\"structuralRelevance\":\"High. Captures the distinct regulatory and benefit-design constraints that materially shape access in the MA channel.\",\"keySimilarities\":[\"Benefit-channel restrictions\",\"CMS statutory/regulatory limits\",\"Plan-level UM within constrained coverage\",\"Commercial vs MA divergence\"],\"keyDifferences\":[\"Channel-specific, not cross-category comparative\",\"Less informative about competitive contracting than about regulatory access\"],\"scores\":{\"budgetImpactSensitivity\":4,\"evidenceThresholdOutcomesRequirement\":3,\"utilizationManagementIntensity\":4,\"contractingRebateLeverage\":2,\"chronicTherapyPersistenceChallenge\":4,\"weightedScore\":3.5},\"decision\":\"Select as a channel analog, not a broad therapeutic analog. Valuable for MA interpretation and launch planning.\"},\"Obesity surgery coverage management\":{\"structuralRelevance\":\"Moderate. Payers use stringent criteria for an obesity intervention with long-term outcome expectations and high budget scrutiny.\",\"keySimilarities\":[\"Obesity as chronic disease framing\",\"Strict clinical eligibility criteria\",\"Need to show durable benefit\",\"Cost-offset logic\"],\"keyDifferences\":[\"Procedure rather than drug\",\"One-time/intermittent cost profile\",\"Different access pathway and stakeholder dynamics\"],\"scores\":{\"budgetImpactSensitivity\":4,\"evidenceThresholdOutcomesRequirement\":4,\"utilizationManagementIntensity\":4,\"contractingRebateLeverage\":1,\"chronicTherapyPersistenceChallenge\":1,\"weightedScore\":3},\"decision\":\"Reject. Helpful for obesity framing, but weak for pharmacy-access, rebate, and persistence questions.\"}}}",
  "providerResponseId": "resp_008b9f8a26206bec006a04e0511c0881a3afc46bd6b9bbb704"
}

{
  "output": {
    "analogAnalysis": {
      "watchouts": [
        "Do not overgeneralize PCSK9 population logic to obesity",
        "Do not assume commercial payer behavior equals MA behavior",
        "Public policies may lag real-world adjudication",
        "Outcomes-based contracts may be underreported or confidential"
      ],
      "rejectedAnalogs": [
        {
          "name": "Hepatitis C direct-acting antiviral coverage expansion",
          "reason": "Curative short-course model makes persistence and chronic budget management less comparable."
        },
        {
          "name": "Obesity surgery coverage management",
          "reason": "Good obesity framing, but weak for pharmacy access, rebate leverage, and chronic medication persistence."
        },
        {
          "name": "GLP-1 obesity payer management",
          "reason": "Target domain, not a comparative analog."
        }
      ],
      "secondaryAnalog": [
        {
          "name": "Specialty biologics for inflammatory disease",
          "caveats": [
            "Lower relevance to obesity-specific cost offsets and public controversy",
            "More mature clinical pathways"
          ],
          "useCases": "Supporting UM pattern benchmarks",
          "whyItTransfers": "Useful secondary comparator for chronic specialty-drug UM and switching strategies.",
          "transferablePatterns": [
            "Step therapy and reauthorization are common",
            "Preferred-product strategies and switching can shape access",
            "Persistence affects payer economics"
          ]
        }
      ],
      "selectedAnalogs": [
        {
          "name": "PCSK9 inhibitor access management",
          "caveats": [
            "PCSK9 has a narrower, more defined prevention population",
            "Obesity drugs face more lifestyle/benefit-design pushback",
            "Utilization pressure is larger in obesity"
          ],
          "useCases": "Commercial payer strategy, formulary defense, outcomes-based contracting framing",
          "whyItTransfers": "Best broad analog for chronic, high-cost pharmacy access with PA, continuation rules, and rebate-driven positioning.",
          "transferablePatterns": [
            "Use clinical thresholds plus reauthorization based on response",
            "Expect payer demand for long-term outcomes evidence",
            "Rebate depth can determine preferred formulary status",
            "Budget impact drives tight utilization management"
          ]
        },
        {
          "name": "Anti-obesity pharmacotherapy under Medicare Advantage constraints",
          "caveats": [
            "Channel-specific; weak for cross-category commercial analogies",
            "Less informative on rebate mechanics"
          ],
          "useCases": "MA launch planning, policy interpretation, segmentation by channel",
          "whyItTransfers": "Best channel analog for MA-specific statutory and benefit-design restrictions.",
          "transferablePatterns": [
            "MA access is constrained by CMS rules, not just plan preference",
            "Coverage divergence vs commercial is structural",
            "UM remains important even where access exists"
          ]
        }
      ],
      "crossCuttingTransferablePatterns": [
        "Payers want clear eligibility gates and continuation criteria",
        "Evidence for durable outcomes matters more than short-term efficacy alone",
        "Budget impact and prevalence drive tighter access controls",
        "Contracting/rebates can unlock preferred status when clinical differentiation is limited",
        "Channel-specific rules can override clinical logic, especially in MA"
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"analogAnalysis\":{\"selectedAnalogs\":[{\"name\":\"PCSK9 inhibitor access management\",\"whyItTransfers\":\"Best broad analog for chronic, high-cost pharmacy access with PA, continuation rules, and rebate-driven positioning.\",\"transferablePatterns\":[\"Use clinical thresholds plus reauthorization based on response\",\"Expect payer demand for long-term outcomes evidence\",\"Rebate depth can determine preferred formulary status\",\"Budget impact drives tight utilization management\"],\"caveats\":[\"PCSK9 has a narrower, more defined prevention population\",\"Obesity drugs face more lifestyle/benefit-design pushback\",\"Utilization pressure is larger in obesity\"],\"useCases\":\"Commercial payer strategy, formulary defense, outcomes-based contracting framing\"},{\"name\":\"Anti-obesity pharmacotherapy under Medicare Advantage constraints\",\"whyItTransfers\":\"Best channel analog for MA-specific statutory and benefit-design restrictions.\",\"transferablePatterns\":[\"MA access is constrained by CMS rules, not just plan preference\",\"Coverage divergence vs commercial is structural\",\"UM remains important even where access exists\"],\"caveats\":[\"Channel-specific; weak for cross-category commercial analogies\",\"Less informative on rebate mechanics\"],\"useCases\":\"MA launch planning, policy interpretation, segmentation by channel\"}],\"secondaryAnalog\":[{\"name\":\"Specialty biologics for inflammatory disease\",\"whyItTransfers\":\"Useful secondary comparator for chronic specialty-drug UM and switching strategies.\",\"transferablePatterns\":[\"Step therapy and reauthorization are common\",\"Preferred-product strategies and switching can shape access\",\"Persistence affects payer economics\"],\"caveats\":[\"Lower relevance to obesity-specific cost offsets and public controversy\",\"More mature clinical pathways\"],\"useCases\":\"Supporting UM pattern benchmarks\"}],\"rejectedAnalogs\":[{\"name\":\"Hepatitis C direct-acting antiviral coverage expansion\",\"reason\":\"Curative short-course model makes persistence and chronic budget management less comparable.\"},{\"name\":\"Obesity surgery coverage management\",\"reason\":\"Good obesity framing, but weak for pharmacy access, rebate leverage, and chronic medication persistence.\"},{\"name\":\"GLP-1 obesity payer management\",\"reason\":\"Target domain, not a comparative analog.\"}],\"crossCuttingTransferablePatterns\":[\"Payers want clear eligibility gates and continuation criteria\",\"Evidence for durable outcomes matters more than short-term efficacy alone\",\"Budget impact and prevalence drive tighter access controls\",\"Contracting/rebates can unlock preferred status when clinical differentiation is limited\",\"Channel-specific rules can override clinical logic, especially in MA\"],\"watchouts\":[\"Do not overgeneralize PCSK9 population logic to obesity\",\"Do not assume commercial payer behavior equals MA behavior\",\"Public policies may lag real-world adjudication\",\"Outcomes-based contracts may be underreported or confidential\"]}}",
  "providerResponseId": "resp_0beb2ec3bdcf3529006a04e05b6f9481a38dbd9c7581cfc84e"
}

{
  "output": {
    "evidence": {
      "records": [
        {
          "id": "src1",
          "url": "https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge",
          "flags": [
            "date_future_relative_to_current_date"
          ],
          "title": "Medicare GLP-1 Bridge | CMS",
          "claims": [
            "CMS announced a short-term Medicare GLP-1 Bridge beginning in July 2026.",
            "Eligible beneficiaries must meet prior authorization criteria and be enrolled in specific Part D / MA-PD plan types.",
            "CMS notes covered uses under the basic Part D benefit, including Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea."
          ],
          "suspicion": "published date is in the future relative to current date; verify authenticity/timestamp",
          "sourceType": "CMS guidance / program page",
          "publishedDate": "2025-12-23"
        },
        {
          "id": "src2",
          "url": "https://www.cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical-changes-medicare-advantage-program-medicare-prescription-final",
          "flags": [],
          "title": "Contract Year 2026 Policy and Technical Changes to MA/Part D | CMS",
          "claims": [
            "CMS did not finalize the proposed Part D coverage of anti-obesity medications for 2026.",
            "This preserves the longstanding statutory constraint on broad obesity-drug coverage in Medicare Advantage/Part D."
          ],
          "sourceType": "CMS fact sheet",
          "publishedDate": "2025-04-04"
        },
        {
          "id": "src3",
          "url": "https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf",
          "flags": [
            "title_source_mismatch"
          ],
          "title": "Aetna Medicare HIDE (HMO D-SNP) Medicaid Weight Loss Prior Authorization Criteria",
          "claims": [
            "Aetna's criteria show active utilization management for anti-obesity GLP-1s.",
            "The criteria include restrictions that the member not use another drug in the class concurrently.",
            "The criteria include prescriber attestation language limiting use for weight-loss indications."
          ],
          "suspicion": "title mixes Medicare HIDE (HMO D-SNP) and Medicaid weight loss criteria; likely mislabeled or conflated document context",
          "sourceType": "Payer prior authorization policy",
          "publishedDate": "2025-12-12"
        }
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"evidence\":{\"records\":[{\"id\":\"src1\",\"url\":\"https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge\",\"title\":\"Medicare GLP-1 Bridge | CMS\",\"sourceType\":\"CMS guidance / program page\",\"publishedDate\":\"2025-12-23\",\"claims\":[\"CMS announced a short-term Medicare GLP-1 Bridge beginning in July 2026.\",\"Eligible beneficiaries must meet prior authorization criteria and be enrolled in specific Part D / MA-PD plan types.\",\"CMS notes covered uses under the basic Part D benefit, including Wegovy for cardiovascular risk reduction and Zepbound for obstructive sleep apnea.\"],\"flags\":[\"date_future_relative_to_current_date\"],\"suspicion\":\"published date is in the future relative to current date; verify authenticity/timestamp\"},{\"id\":\"src2\",\"url\":\"https://www.cms.gov/newsroom/fact-sheets/contract-year-2026-policy-and-technical-changes-medicare-advantage-program-medicare-prescription-final\",\"title\":\"Contract Year 2026 Policy and Technical Changes to MA/Part D | CMS\",\"sourceType\":\"CMS fact sheet\",\"publishedDate\":\"2025-04-04\",\"claims\":[\"CMS did not finalize the proposed Part D coverage of anti-obesity medications for 2026.\",\"This preserves the longstanding statutory constraint on broad obesity-drug coverage in Medicare Advantage/Part D.\"],\"flags\":[]},{\"id\":\"src3\",\"url\":\"https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf\",\"title\":\"Aetna Medicare HIDE (HMO D-SNP) Medicaid Weight Loss Prior Authorization Criteria\",\"sourceType\":\"Payer prior authorization policy\",\"publishedDate\":\"2025-12-12\",\"claims\":[\"Aetna's criteria show active utilization management for anti-obesity GLP-1s.\",\"The criteria include restrictions that the member not use another drug in the class concurrently.\",\"The criteria include prescriber attestation language limiting use for weight-loss indications.\"],\"flags\":[\"title_source_mismatch\"],\"suspicion\":\"title mixes Medicare HIDE (HMO D-SNP) and Medicaid weight loss criteria; likely mislabeled or conflated document context\"}]}}",
  "providerResponseId": "resp_06553a6cbf1a0a36006a04e061798c819e961a3d3ac34f6d56"
}

{
  "output": {
    "claimRecord": {
      "claims": [
        {
          "claim": "Major commercial payers are increasingly covering anti-obesity GLP-1s under pharmacy benefits but typically require prior authorization with BMI/comorbidity criteria, documentation of prior lifestyle intervention, and no concurrent GLP-1 use.",
          "support": [
            "marketScan.coveragePolicyLandscape",
            "marketScan.utilizationManagementControls",
            "src3"
          ]
        },
        {
          "claim": "A common continuation rule is reauthorization after 3-6 months only if patients show meaningful response, such as at least 5% weight loss or adherence above ~80% possession ratio.",
          "support": [
            "marketScan.utilizationManagementControls"
          ]
        },
        {
          "claim": "Medicare Advantage remains structurally constrained: CMS did not finalize broad Part D coverage of anti-obesity drugs for 2026, preserving access barriers despite a narrow GLP-1 Bridge program slated for July 2026.",
          "support": [
            "src2",
            "src1",
            "marketScan.medicareAdvantageConstraints"
          ]
        },
        {
          "claim": "Payers are likely to value longer-duration evidence, cardiovascular outcomes, and comorbidity improvement—especially for diabetes, hypertension, and sleep apnea—more than short-term weight-loss efficacy alone.",
          "support": [
            "marketScan.evidenceExpectationsAndValueDrivers"
          ]
        },
        {
          "claim": "Anti-obesity GLP-1s are generally positioned as mid-to-specialty therapies with 20%-30% coinsurance, and manufacturers should expect rebate and value-based contracting pressure tied to persistence and clinical milestones.",
          "support": [
            "marketScan.formularyPositioningAndContracting"
          ]
        },
        {
          "claim": "PCSK9 inhibitor access management is the best broad analog: it shows how payers use clinical thresholds, reauthorization based on response, and rebates to control access for high-cost chronic therapies.",
          "support": [
            "analogAnalysis.selectedAnalogs"
          ]
        }
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"claimRecord\":{\"claims\":[{\"claim\":\"Major commercial payers are increasingly covering anti-obesity GLP-1s under pharmacy benefits but typically require prior authorization with BMI/comorbidity criteria, documentation of prior lifestyle intervention, and no concurrent GLP-1 use.\",\"support\":[\"marketScan.coveragePolicyLandscape\",\"marketScan.utilizationManagementControls\",\"src3\"]},{\"claim\":\"A common continuation rule is reauthorization after 3-6 months only if patients show meaningful response, such as at least 5% weight loss or adherence above ~80% possession ratio.\",\"support\":[\"marketScan.utilizationManagementControls\"]},{\"claim\":\"Medicare Advantage remains structurally constrained: CMS did not finalize broad Part D coverage of anti-obesity drugs for 2026, preserving access barriers despite a narrow GLP-1 Bridge program slated for July 2026.\",\"support\":[\"src2\",\"src1\",\"marketScan.medicareAdvantageConstraints\"]},{\"claim\":\"Payers are likely to value longer-duration evidence, cardiovascular outcomes, and comorbidity improvement—especially for diabetes, hypertension, and sleep apnea—more than short-term weight-loss efficacy alone.\",\"support\":[\"marketScan.evidenceExpectationsAndValueDrivers\"]},{\"claim\":\"Anti-obesity GLP-1s are generally positioned as mid-to-specialty therapies with 20%-30% coinsurance, and manufacturers should expect rebate and value-based contracting pressure tied to persistence and clinical milestones.\",\"support\":[\"marketScan.formularyPositioningAndContracting\"]},{\"claim\":\"PCSK9 inhibitor access management is the best broad analog: it shows how payers use clinical thresholds, reauthorization based on response, and rebates to control access for high-cost chronic therapies.\",\"support\":[\"analogAnalysis.selectedAnalogs\"]}]}}",
  "providerResponseId": "resp_036528a921bae782006a04e064db0881a1af05011e826c9fe4"
}

{
  "output": {
    "challengeOutput": {
      "caveats": [
        "The evidence base is narrow, stale, and partly indirect.",
        "The Aetna document appears mislabeled/conflated (HIDE/D-SNP vs Medicaid weight loss), so it should not anchor broad conclusions.",
        "Public policy documents may lag adjudication and employer-specific exceptions.",
        "The future-dated CMS source needs authenticity/timestamp verification before use.",
        "Commercial and MA behavior should remain separated; do not generalize one channel to the other."
      ],
      "claimLevelRevisions": [
        {
          "claim": "Major commercial payers are increasingly covering anti-obesity GLP-1s under pharmacy benefits but typically require prior authorization with BMI/comorbidity criteria, documentation of prior lifestyle intervention, and no concurrent GLP-1 use.",
          "caveats": [
            "Evidence is thin and partially indirect.",
            "Aetna source is a Medicare HIDE/D-SNP document, not a representative commercial payer policy.",
            "'Increasingly covering' is not established from the cited sources."
          ],
          "revision": "Commercial coverage is heterogeneous and not well documented publicly; some plans cover anti-obesity GLP-1s under pharmacy benefits with prior authorization that may include BMI/comorbidity thresholds, prior lifestyle attempts, and class exclusions, but the draft overstates how broadly this applies and relies too heavily on a single Aetna D-SNP policy to infer major commercial behavior.",
          "unresolvedQuestions": [
            "How many major commercial plans actually cover obesity GLP-1s today?",
            "Which criteria are consistently used across national payers vs employer-specific plans?"
          ],
          "confidenceAdjustment": "Downward: from moderate to low-moderate."
        },
        {
          "claim": "A common continuation rule is reauthorization after 3-6 months only if patients show meaningful response, such as at least 5% weight loss or adherence above ~80% possession ratio.",
          "caveats": [
            "Single-source support only.",
            "Could reflect one plan or a small subset of plans.",
            "Possession ratio thresholds may be operational, not clinical, and may not be publicly visible."
          ],
          "revision": "Some payer policies appear to use short-interval reauthorization tied to response, but the exact timing and thresholds are not established as common across payers; the 3-6 month / 5% / 80% figures should be treated as examples rather than a market norm.",
          "unresolvedQuestions": [
            "How frequent are 3-month vs 6-month reauthorizations?",
            "Are weight-loss thresholds standardized or plan-specific?"
          ],
          "confidenceAdjustment": "Downward: from moderate to low."
        },
        {
          "claim": "Medicare Advantage remains structurally constrained: CMS did not finalize broad Part D coverage of anti-obesity drugs for 2026, preserving access barriers despite a narrow GLP-1 Bridge program slated for July 2026.",
          "caveats": [
            "Future-dated CMS source is flagged as suspicious.",
            "The bridge program may be inaccurate, incomplete, or not yet valid.",
            "MA-specific access rules can differ by product and plan type."
          ],
          "revision": "CMS did not finalize broad Part D coverage of anti-obesity drugs for 2026, so Medicare access remains constrained; however, the alleged July 2026 'GLP-1 Bridge' program should be treated with caution because the cited CMS page is future-dated relative to the current date and may be unreliable or mis-timestamped.",
          "unresolvedQuestions": [
            "Does the bridge program exist in its described form?",
            "What exact plans/enrollees would be eligible?"
          ],
          "confidenceAdjustment": "Split confidence: high on the 2026 coverage exclusion; low on the bridge-program claim."
        },
        {
          "claim": "Payers are likely to value longer-duration evidence, cardiovascular outcomes, and comorbidity improvement—especially for diabetes, hypertension, and sleep apnea—more than short-term weight-loss efficacy alone.",
          "caveats": [
            "This is largely inferential.",
            "CMS coverage references do not prove broader payer valuation priorities.",
            "Different plan types may prioritize budget impact over outcomes evidence."
          ],
          "revision": "Payers may value durability and comorbidity outcomes in addition to short-term weight loss, but the hierarchy of evidence preferences is not directly demonstrated by the sources; the claim should be framed as a plausible inference rather than a documented payer standard.",
          "unresolvedQuestions": [
            "Which endpoints do payers explicitly cite in obesity policy rationales?",
            "Is CV outcomes evidence actually decisive for access, or merely supportive?"
          ],
          "confidenceAdjustment": "Downward: from moderate to low-moderate."
        },
        {
          "claim": "Anti-obesity GLP-1s are generally positioned as mid-to-specialty therapies with 20%-30% coinsurance, and manufacturers should expect rebate and value-based contracting pressure tied to persistence and clinical milestones.",
          "caveats": [
            "No broad formulary survey is provided.",
            "20%-30% coinsurance appears unverified.",
            "No public outcomes-based contracts were actually identified."
          ],
          "revision": "The draft does not adequately support a general market-wide formulary placement or coinsurance range for anti-obesity GLP-1s. At most, some plans may place these drugs on higher-cost tiers with significant cost sharing; rebate and value-based contracting pressure is plausible but not evidenced here and outcomes-based deals are not shown.",
          "unresolvedQuestions": [
            "What is the actual tiering/cost-sharing distribution across major plans?",
            "Are any outcomes-based contracts public or only rumored/confidential?"
          ],
          "confidenceAdjustment": "Downward: from low-moderate to low."
        },
        {
          "claim": "PCSK9 inhibitor access management is the best broad analog: it shows how payers use clinical thresholds, reauthorization based on response, and rebates to control access for high-cost chronic therapies.",
          "caveats": [
            "Population and indication dynamics differ materially.",
            "PCSK9 has a narrower, clearer prevention population.",
            "The analog may overstate the role of outcomes evidence relative to rebate leverage."
          ],
          "revision": "PCSK9 access management is a workable but imperfect analog, mainly for chronic high-cost pharmacy access, PA, and rebate-driven positioning. It should not be described as 'best' without comparing against other plausible analogs and acknowledging that obesity faces much broader population pressure and more lifestyle/benefit-design pushback.",
          "unresolvedQuestions": [
            "Is PCSK9 truly more informative than other specialty chronic classes?",
            "Which analog best captures obesity-specific stigma and benefit-design resistance?"
          ],
          "confidenceAdjustment": "Moderate, but downgrade the 'best' qualifier to low confidence."
        }
      ],
      "unresolvedQuestions": [
        "What are the current policies of the largest national commercial payers and PBMs beyond Aetna?",
        "How much of obesity GLP-1 access is employer-group-driven vs payer-driven?",
        "What continuation criteria are actually applied operationally versus written in policies?",
        "Are any value-based or outcomes-based obesity contracts publicly documented?",
        "What is the real status of the claimed CMS GLP-1 Bridge program?"
      ],
      "confidenceAdjustments": [
        {
          "area": "Commercial coverage landscape",
          "adjustment": "Reduce certainty; avoid implying broad national consistency from sparse public documentation."
        },
        {
          "area": "Utilization management patterns",
          "adjustment": "Reduce certainty; distinguish documented examples from general market norms."
        },
        {
          "area": "MA/Part D policy",
          "adjustment": "High confidence on continued statutory constraint; low confidence on the bridge-program details pending source validation."
        },
        {
          "area": "Evidence expectations",
          "adjustment": "Frame as hypothesis/inference unless payer-cited evidence is directly documented."
        },
        {
          "area": "Contracting assumptions",
          "adjustment": "Treat as speculative; remove implied prevalence of outcomes-based contracting."
        },
        {
          "area": "Analog choice",
          "adjustment": "Keep PCSK9 as secondary/qualified analog, not definitive best analog."
        }
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"challengeOutput\":{\"claimLevelRevisions\":[{\"claim\":\"Major commercial payers are increasingly covering anti-obesity GLP-1s under pharmacy benefits but typically require prior authorization with BMI/comorbidity criteria, documentation of prior lifestyle intervention, and no concurrent GLP-1 use.\",\"revision\":\"Commercial coverage is heterogeneous and not well documented publicly; some plans cover anti-obesity GLP-1s under pharmacy benefits with prior authorization that may include BMI/comorbidity thresholds, prior lifestyle attempts, and class exclusions, but the draft overstates how broadly this applies and relies too heavily on a single Aetna D-SNP policy to infer major commercial behavior.\",\"confidenceAdjustment\":\"Downward: from moderate to low-moderate.\",\"caveats\":[\"Evidence is thin and partially indirect.\",\"Aetna source is a Medicare HIDE/D-SNP document, not a representative commercial payer policy.\",\"'Increasingly covering' is not established from the cited sources.\"],\"unresolvedQuestions\":[\"How many major commercial plans actually cover obesity GLP-1s today?\",\"Which criteria are consistently used across national payers vs employer-specific plans?\"]},{\"claim\":\"A common continuation rule is reauthorization after 3-6 months only if patients show meaningful response, such as at least 5% weight loss or adherence above ~80% possession ratio.\",\"revision\":\"Some payer policies appear to use short-interval reauthorization tied to response, but the exact timing and thresholds are not established as common across payers; the 3-6 month / 5% / 80% figures should be treated as examples rather than a market norm.\",\"confidenceAdjustment\":\"Downward: from moderate to low.\",\"caveats\":[\"Single-source support only.\",\"Could reflect one plan or a small subset of plans.\",\"Possession ratio thresholds may be operational, not clinical, and may not be publicly visible.\"],\"unresolvedQuestions\":[\"How frequent are 3-month vs 6-month reauthorizations?\",\"Are weight-loss thresholds standardized or plan-specific?\"]},{\"claim\":\"Medicare Advantage remains structurally constrained: CMS did not finalize broad Part D coverage of anti-obesity drugs for 2026, preserving access barriers despite a narrow GLP-1 Bridge program slated for July 2026.\",\"revision\":\"CMS did not finalize broad Part D coverage of anti-obesity drugs for 2026, so Medicare access remains constrained; however, the alleged July 2026 'GLP-1 Bridge' program should be treated with caution because the cited CMS page is future-dated relative to the current date and may be unreliable or mis-timestamped.\",\"confidenceAdjustment\":\"Split confidence: high on the 2026 coverage exclusion; low on the bridge-program claim.\",\"caveats\":[\"Future-dated CMS source is flagged as suspicious.\",\"The bridge program may be inaccurate, incomplete, or not yet valid.\",\"MA-specific access rules can differ by product and plan type.\"],\"unresolvedQuestions\":[\"Does the bridge program exist in its described form?\",\"What exact plans/enrollees would be eligible?\"]},{\"claim\":\"Payers are likely to value longer-duration evidence, cardiovascular outcomes, and comorbidity improvement—especially for diabetes, hypertension, and sleep apnea—more than short-term weight-loss efficacy alone.\",\"revision\":\"Payers may value durability and comorbidity outcomes in addition to short-term weight loss, but the hierarchy of evidence preferences is not directly demonstrated by the sources; the claim should be framed as a plausible inference rather than a documented payer standard.\",\"confidenceAdjustment\":\"Downward: from moderate to low-moderate.\",\"caveats\":[\"This is largely inferential.\",\"CMS coverage references do not prove broader payer valuation priorities.\",\"Different plan types may prioritize budget impact over outcomes evidence.\"],\"unresolvedQuestions\":[\"Which endpoints do payers explicitly cite in obesity policy rationales?\",\"Is CV outcomes evidence actually decisive for access, or merely supportive?\"]},{\"claim\":\"Anti-obesity GLP-1s are generally positioned as mid-to-specialty therapies with 20%-30% coinsurance, and manufacturers should expect rebate and value-based contracting pressure tied to persistence and clinical milestones.\",\"revision\":\"The draft does not adequately support a general market-wide formulary placement or coinsurance range for anti-obesity GLP-1s. At most, some plans may place these drugs on higher-cost tiers with significant cost sharing; rebate and value-based contracting pressure is plausible but not evidenced here and outcomes-based deals are not shown.\",\"confidenceAdjustment\":\"Downward: from low-moderate to low.\",\"caveats\":[\"No broad formulary survey is provided.\",\"20%-30% coinsurance appears unverified.\",\"No public outcomes-based contracts were actually identified.\"],\"unresolvedQuestions\":[\"What is the actual tiering/cost-sharing distribution across major plans?\",\"Are any outcomes-based contracts public or only rumored/confidential?\"]},{\"claim\":\"PCSK9 inhibitor access management is the best broad analog: it shows how payers use clinical thresholds, reauthorization based on response, and rebates to control access for high-cost chronic therapies.\",\"revision\":\"PCSK9 access management is a workable but imperfect analog, mainly for chronic high-cost pharmacy access, PA, and rebate-driven positioning. It should not be described as 'best' without comparing against other plausible analogs and acknowledging that obesity faces much broader population pressure and more lifestyle/benefit-design pushback.\",\"confidenceAdjustment\":\"Moderate, but downgrade the 'best' qualifier to low confidence.\",\"caveats\":[\"Population and indication dynamics differ materially.\",\"PCSK9 has a narrower, clearer prevention population.\",\"The analog may overstate the role of outcomes evidence relative to rebate leverage.\"],\"unresolvedQuestions\":[\"Is PCSK9 truly more informative than other specialty chronic classes?\",\"Which analog best captures obesity-specific stigma and benefit-design resistance?\"]}],\"confidenceAdjustments\":[{\"area\":\"Commercial coverage landscape\",\"adjustment\":\"Reduce certainty; avoid implying broad national consistency from sparse public documentation.\"},{\"area\":\"Utilization management patterns\",\"adjustment\":\"Reduce certainty; distinguish documented examples from general market norms.\"},{\"area\":\"MA/Part D policy\",\"adjustment\":\"High confidence on continued statutory constraint; low confidence on the bridge-program details pending source validation.\"},{\"area\":\"Evidence expectations\",\"adjustment\":\"Frame as hypothesis/inference unless payer-cited evidence is directly documented.\"},{\"area\":\"Contracting assumptions\",\"adjustment\":\"Treat as speculative; remove implied prevalence of outcomes-based contracting.\"},{\"area\":\"Analog choice\",\"adjustment\":\"Keep PCSK9 as secondary/qualified analog, not definitive best analog.\"}],\"caveats\":[\"The evidence base is narrow, stale, and partly indirect.\",\"The Aetna document appears mislabeled/conflated (HIDE/D-SNP vs Medicaid weight loss), so it should not anchor broad conclusions.\",\"Public policy documents may lag adjudication and employer-specific exceptions.\",\"The future-dated CMS source needs authenticity/timestamp verification before use.\",\"Commercial and MA behavior should remain separated; do not generalize one channel to the other.\"],\"unresolvedQuestions\":[\"What are the current policies of the largest national commercial payers and PBMs beyond Aetna?\",\"How much of obesity GLP-1 access is employer-group-driven vs payer-driven?\",\"What continuation criteria are actually applied operationally versus written in policies?\",\"Are any value-based or outcomes-based obesity contracts publicly documented?\",\"What is the real status of the claimed CMS GLP-1 Bridge program?\"]}}",
  "providerResponseId": "resp_076004f6ac2a84c1006a04e068cb648194bf8ea2a91a2d2857"
}

{
  "output": {
    "calibratedClaimRecord": {
      "claims": [
        {
          "claim": "Major commercial payers are increasingly covering anti-obesity GLP-1s under pharmacy benefits but typically require prior authorization with BMI/comorbidity criteria, documentation of prior lifestyle intervention, and no concurrent GLP-1 use.",
          "flags": {
            "is_unsupported": false,
            "requires_human_review": true,
            "contains_suspicious_source": true,
            "support_count_below_threshold": false
          },
          "caveats": [
            "Evidence is thin and partially indirect.",
            "Aetna source is a Medicare HIDE/D-SNP document, not a representative commercial payer policy.",
            "'Increasingly covering' is not established from the cited sources."
          ],
          "support": [
            "marketScan.coveragePolicyLandscape",
            "marketScan.utilizationManagementControls",
            "src3"
          ],
          "confidence": "low-moderate",
          "support_count": 3,
          "human_correction": {
            "suggestedAction": "Gather broader commercial payer or PBM policy documents beyond Aetna to confirm coverage patterns and criteria consistency.",
            "unresolvedQuestions": [
              "How many major commercial plans actually cover obesity GLP-1s today?",
              "Which criteria are consistently used across national payers vs employer-specific plans?"
            ]
          },
          "confidenceAdjustment": "Downward: from moderate to low-moderate."
        },
        {
          "claim": "A common continuation rule is reauthorization after 3-6 months only if patients show meaningful response, such as at least 5% weight loss or adherence above ~80% possession ratio.",
          "flags": {
            "is_unsupported": false,
            "requires_human_review": true,
            "contains_suspicious_source": false,
            "support_count_below_threshold": true
          },
          "caveats": [
            "Single-source support only.",
            "Could reflect one plan or a small subset of plans.",
            "Possession ratio thresholds may be operational, not clinical, and may not be publicly visible."
          ],
          "support": [
            "marketScan.utilizationManagementControls"
          ],
          "confidence": "low",
          "support_count": 1,
          "human_correction": {
            "suggestedAction": "Collect reauthorization criteria from multiple payer policies to establish common thresholds and intervals.",
            "unresolvedQuestions": [
              "How frequent are 3-month vs 6-month reauthorizations?",
              "Are weight-loss thresholds standardized or plan-specific?"
            ]
          },
          "confidenceAdjustment": "Downward: from moderate to low."
        },
        {
          "claim": "Medicare Advantage remains structurally constrained: CMS did not finalize broad Part D coverage of anti-obesity drugs for 2026, preserving access barriers despite a narrow GLP-1 Bridge program slated for July 2026.",
          "flags": {
            "is_unsupported": false,
            "requires_human_review": true,
            "contains_suspicious_source": true,
            "support_count_below_threshold": false
          },
          "caveats": [
            "Future-dated CMS source is flagged as suspicious.",
            "The bridge program may be inaccurate, incomplete, or not yet valid.",
            "MA-specific access rules can differ by product and plan type."
          ],
          "support": [
            "src2",
            "src1",
            "marketScan.medicareAdvantageConstraints"
          ],
          "confidence": "split (high on coverage exclusion; low on bridge-program)",
          "support_count": 3,
          "human_correction": {
            "suggestedAction": "Validate the GLP-1 Bridge program details via CMS communications or plan-level documentation to confirm timing and eligibility.",
            "unresolvedQuestions": [
              "Does the bridge program exist in its described form?",
              "What exact plans/enrollees would be eligible?"
            ]
          },
          "confidenceAdjustment": "Split confidence: high on the 2026 coverage exclusion; low on the bridge-program claim."
        },
        {
          "claim": "Payers are likely to value longer-duration evidence, cardiovascular outcomes, and comorbidity improvement—especially for diabetes, hypertension, and sleep apnea—more than short-term weight-loss efficacy alone.",
          "flags": {
            "is_unsupported": false,
            "requires_human_review": true,
            "contains_suspicious_source": false,
            "support_count_below_threshold": true
          },
          "caveats": [
            "This is largely inferential.",
            "CMS coverage references do not prove broader payer valuation priorities.",
            "Different plan types may prioritize budget impact over outcomes evidence."
          ],
          "support": [
            "marketScan.evidenceExpectationsAndValueDrivers"
          ],
          "confidence": "low-moderate",
          "support_count": 1,
          "human_correction": {
            "suggestedAction": "Review payer medical policy rationales and advisory-board summaries to document explicit evidence preferences.",
            "unresolvedQuestions": [
              "Which endpoints do payers explicitly cite in obesity policy rationales?",
              "Is CV outcomes evidence actually decisive for access, or merely supportive?"
            ]
          },
          "confidenceAdjustment": "Downward: from moderate to low-moderate."
        },
        {
          "claim": "Anti-obesity GLP-1s are generally positioned as mid-to-specialty therapies with 20%-30% coinsurance, and manufacturers should expect rebate and value-based contracting pressure tied to persistence and clinical milestones.",
          "flags": {
            "is_unsupported": false,
            "requires_human_review": true,
            "contains_suspicious_source": false,
            "support_count_below_threshold": true
          },
          "caveats": [
            "No broad formulary survey is provided.",
            "20%-30% coinsurance appears unverified.",
            "No public outcomes-based contracts were actually identified."
          ],
          "support": [
            "marketScan.formularyPositioningAndContracting"
          ],
          "confidence": "low",
          "support_count": 1,
          "human_correction": {
            "suggestedAction": "Gather formulary placement and cost-share data from multiple PBMs and commercial plans; seek any public or semi-public contracting examples.",
            "unresolvedQuestions": [
              "What is the actual tiering/cost-sharing distribution across major plans?",
              "Are any outcomes-based contracts public or only rumored/confidential?"
            ]
          },
          "confidenceAdjustment": "Downward: from low-moderate to low."
        },
        {
          "claim": "PCSK9 inhibitor access management is the best broad analog: it shows how payers use clinical thresholds, reauthorization based on response, and rebates to control access for high-cost chronic therapies.",
          "flags": {
            "is_unsupported": false,
            "requires_human_review": true,
            "contains_suspicious_source": false,
            "support_count_below_threshold": true
          },
          "caveats": [
            "Population and indication dynamics differ materially.",
            "PCSK9 has a narrower, clearer prevention population.",
            "The analog may overstate the role of outcomes evidence relative to rebate leverage."
          ],
          "support": [
            "analogAnalysis.selectedAnalogs"
          ],
          "confidence": "low",
          "support_count": 1,
          "human_correction": {
            "suggestedAction": "Consider alternative analogs and document rationale for selecting PCSK9 over other classes; validate with additional payer interviews.",
            "unresolvedQuestions": [
              "Is PCSK9 truly more informative than other specialty chronic classes?",
              "Which analog best captures obesity-specific stigma and benefit-design resistance?"
            ]
          },
          "confidenceAdjustment": "Moderate, but downgrade the 'best' qualifier to low confidence."
        }
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"calibratedClaimRecord\":{\"claims\":[{\"claim\":\"Major commercial payers are increasingly covering anti-obesity GLP-1s under pharmacy benefits but typically require prior authorization with BMI/comorbidity criteria, documentation of prior lifestyle intervention, and no concurrent GLP-1 use.\",\"support\":[\"marketScan.coveragePolicyLandscape\",\"marketScan.utilizationManagementControls\",\"src3\"],\"support_count\":3,\"flags\":{\"requires_human_review\":true,\"support_count_below_threshold\":false,\"is_unsupported\":false,\"contains_suspicious_source\":true},\"confidence\":\"low-moderate\",\"confidenceAdjustment\":\"Downward: from moderate to low-moderate.\",\"caveats\":[\"Evidence is thin and partially indirect.\",\"Aetna source is a Medicare HIDE/D-SNP document, not a representative commercial payer policy.\",\"'Increasingly covering' is not established from the cited sources.\"],\"human_correction\":{\"unresolvedQuestions\":[\"How many major commercial plans actually cover obesity GLP-1s today?\",\"Which criteria are consistently used across national payers vs employer-specific plans?\"],\"suggestedAction\":\"Gather broader commercial payer or PBM policy documents beyond Aetna to confirm coverage patterns and criteria consistency.\"}},{\"claim\":\"A common continuation rule is reauthorization after 3-6 months only if patients show meaningful response, such as at least 5% weight loss or adherence above ~80% possession ratio.\",\"support\":[\"marketScan.utilizationManagementControls\"],\"support_count\":1,\"flags\":{\"requires_human_review\":true,\"support_count_below_threshold\":true,\"is_unsupported\":false,\"contains_suspicious_source\":false},\"confidence\":\"low\",\"confidenceAdjustment\":\"Downward: from moderate to low.\",\"caveats\":[\"Single-source support only.\",\"Could reflect one plan or a small subset of plans.\",\"Possession ratio thresholds may be operational, not clinical, and may not be publicly visible.\"],\"human_correction\":{\"unresolvedQuestions\":[\"How frequent are 3-month vs 6-month reauthorizations?\",\"Are weight-loss thresholds standardized or plan-specific?\"],\"suggestedAction\":\"Collect reauthorization criteria from multiple payer policies to establish common thresholds and intervals.\"}},{\"claim\":\"Medicare Advantage remains structurally constrained: CMS did not finalize broad Part D coverage of anti-obesity drugs for 2026, preserving access barriers despite a narrow GLP-1 Bridge program slated for July 2026.\",\"support\":[\"src2\",\"src1\",\"marketScan.medicareAdvantageConstraints\"],\"support_count\":3,\"flags\":{\"requires_human_review\":true,\"support_count_below_threshold\":false,\"is_unsupported\":false,\"contains_suspicious_source\":true},\"confidence\":\"split (high on coverage exclusion; low on bridge-program)\",\"confidenceAdjustment\":\"Split confidence: high on the 2026 coverage exclusion; low on the bridge-program claim.\",\"caveats\":[\"Future-dated CMS source is flagged as suspicious.\",\"The bridge program may be inaccurate, incomplete, or not yet valid.\",\"MA-specific access rules can differ by product and plan type.\"],\"human_correction\":{\"unresolvedQuestions\":[\"Does the bridge program exist in its described form?\",\"What exact plans/enrollees would be eligible?\"],\"suggestedAction\":\"Validate the GLP-1 Bridge program details via CMS communications or plan-level documentation to confirm timing and eligibility.\"}},{\"claim\":\"Payers are likely to value longer-duration evidence, cardiovascular outcomes, and comorbidity improvement—especially for diabetes, hypertension, and sleep apnea—more than short-term weight-loss efficacy alone.\",\"support\":[\"marketScan.evidenceExpectationsAndValueDrivers\"],\"support_count\":1,\"flags\":{\"requires_human_review\":true,\"support_count_below_threshold\":true,\"is_unsupported\":false,\"contains_suspicious_source\":false},\"confidence\":\"low-moderate\",\"confidenceAdjustment\":\"Downward: from moderate to low-moderate.\",\"caveats\":[\"This is largely inferential.\",\"CMS coverage references do not prove broader payer valuation priorities.\",\"Different plan types may prioritize budget impact over outcomes evidence.\"],\"human_correction\":{\"unresolvedQuestions\":[\"Which endpoints do payers explicitly cite in obesity policy rationales?\",\"Is CV outcomes evidence actually decisive for access, or merely supportive?\"],\"suggestedAction\":\"Review payer medical policy rationales and advisory-board summaries to document explicit evidence preferences.\"}},{\"claim\":\"Anti-obesity GLP-1s are generally positioned as mid-to-specialty therapies with 20%-30% coinsurance, and manufacturers should expect rebate and value-based contracting pressure tied to persistence and clinical milestones.\",\"support\":[\"marketScan.formularyPositioningAndContracting\"],\"support_count\":1,\"flags\":{\"requires_human_review\":true,\"support_count_below_threshold\":true,\"is_unsupported\":false,\"contains_suspicious_source\":false},\"confidence\":\"low\",\"confidenceAdjustment\":\"Downward: from low-moderate to low.\",\"caveats\":[\"No broad formulary survey is provided.\",\"20%-30% coinsurance appears unverified.\",\"No public outcomes-based contracts were actually identified.\"],\"human_correction\":{\"unresolvedQuestions\":[\"What is the actual tiering/cost-sharing distribution across major plans?\",\"Are any outcomes-based contracts public or only rumored/confidential?\"],\"suggestedAction\":\"Gather formulary placement and cost-share data from multiple PBMs and commercial plans; seek any public or semi-public contracting examples.\"}},{\"claim\":\"PCSK9 inhibitor access management is the best broad analog: it shows how payers use clinical thresholds, reauthorization based on response, and rebates to control access for high-cost chronic therapies.\",\"support\":[\"analogAnalysis.selectedAnalogs\"],\"support_count\":1,\"flags\":{\"requires_human_review\":true,\"support_count_below_threshold\":true,\"is_unsupported\":false,\"contains_suspicious_source\":false},\"confidence\":\"low\",\"confidenceAdjustment\":\"Moderate, but downgrade the 'best' qualifier to low confidence.\",\"caveats\":[\"Population and indication dynamics differ materially.\",\"PCSK9 has a narrower, clearer prevention population.\",\"The analog may overstate the role of outcomes evidence relative to rebate leverage.\"],\"human_correction\":{\"unresolvedQuestions\":[\"Is PCSK9 truly more informative than other specialty chronic classes?\",\"Which analog best captures obesity-specific stigma and benefit-design resistance?\"],\"suggestedAction\":\"Consider alternative analogs and document rationale for selecting PCSK9 over other classes; validate with additional payer interviews.\"}}]}}",
  "providerResponseId": "resp_04d20944ab9d285f006a04e0b30a0c8197a29a2e551fe98029"
}

{
  "output": {
    "finalDeliverable": {
      "topFindings": [
        "Utilization management is the clearest pattern: prior authorization, response-based reauthorization, step therapy in some plans, and quantity/specialty-pharmacy controls.",
        "Evidence expectations likely emphasize durable weight control and comorbidity improvement, but this is inferred rather than directly documented as a payer standard.",
        "No public outcomes-based contracts were identified; rebate/value-based contracting pressure is plausible but unproven in the sources provided.",
        "PCSK9 inhibitor access management is the best broad analog for chronic high-cost pharmacy access, but it is only a qualified comparator.",
        "MA access should be handled separately from commercial coverage because statutory constraints override normal payer preference."
      ],
      "bottomLineAnswer": "Bottom line: Commercial coverage for anti-obesity GLP-1s appears heterogeneous and is not well documented publicly; where coverage exists, payers use prior authorization, BMI/comorbidity gates, lifestyle-history documentation, and class-exclusion controls. Medicare Advantage remains structurally constrained by CMS’s decision not to finalize broad Part D coverage for 2026. The evidence base here is thin and partly indirect, so these conclusions should be treated as directional rather than market-wide proof.",
      "supplementalMaterial": {
        "originalStructuredBrief": {
          "depth": "High depth; include both published and gray literature sources",
          "audience": [
            "Market access strategy team",
            "Payer engagement team",
            "HEOR team",
            "Commercial leadership"
          ],
          "objective": "Assess evolving US payer coverage policies, evidence expectations, reimbursement considerations, and market access barriers for obesity therapies to inform payer engagement strategy, value proposition development, and evidence generation planning ahead of launch.",
          "topic_type": "Market access and payer policy research",
          "assumptions": [
            "The request focuses on the US market only.",
            "'Major' payers includes national and large regional commercial payers, PBMs, and Medicare Advantage plans.",
            "Both pharmacy and medical coverage policies may be relevant.",
            "If direct payer evidence is limited, conference insights, advisory boards, and reimbursement trend analyses should be used as supporting sources.",
            "The analysis should preserve ambiguity where payer policies differ materially by plan and geography.",
            "Next-generation GLP-1/GIP therapies are assumed to include emerging obesity agents in this class, without naming a specific product unless evidence requires it."
          ],
          "geographies": [
            "United States"
          ],
          "target_topic": "US payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies",
          "time_horizon": "Current state with emphasis on changes in the last 12-18 months",
          "output_format": "Consulting research brief with payer landscape synthesis, policy trend analysis, and actionable market access implications",
          "target_entities": [
            "Major US commercial payers",
            "Medicare Advantage organizations",
            "PBMs",
            "Regional health plans",
            "Payer medical and pharmacy policy teams",
            "Competitor manufacturers of anti-obesity therapies"
          ],
          "decision_context": "Support launch readiness and market access planning for next-generation GLP-1/GIP anti-obesity therapies by identifying payer coverage criteria, evidence thresholds, utilization management practices, and contracting/value arguments likely to shape reimbursement decisions.",
          "research_question": "How do major US commercial and Medicare Advantage payers currently evaluate and manage coverage for anti-obesity pharmacotherapies, and what evidence, value drivers, and utilization management strategies most influence market access decisions for next-generation GLP-1/GIP therapies?",
          "priority_dimension": [
            "Coverage policy evolution",
            "Prior authorization and step therapy requirements",
            "Formulary positioning",
            "Evidence expectations for long-term outcomes and cardiovascular benefit",
            "Adherence and persistence expectations",
            "Healthcare cost offset rationale",
            "Emerging outcomes-based contracting models"
          ]
        }
      }
    }
  },
  "status": "completed",
  "rawProviderText": "{\"finalDeliverable\":{\"bottomLineAnswer\":\"Bottom line: Commercial coverage for anti-obesity GLP-1s appears heterogeneous and is not well documented publicly; where coverage exists, payers use prior authorization, BMI/comorbidity gates, lifestyle-history documentation, and class-exclusion controls. Medicare Advantage remains structurally constrained by CMS’s decision not to finalize broad Part D coverage for 2026. The evidence base here is thin and partly indirect, so these conclusions should be treated as directional rather than market-wide proof.\",\"topFindings\":[\"Utilization management is the clearest pattern: prior authorization, response-based reauthorization, step therapy in some plans, and quantity/specialty-pharmacy controls.\",\"Evidence expectations likely emphasize durable weight control and comorbidity improvement, but this is inferred rather than directly documented as a payer standard.\",\"No public outcomes-based contracts were identified; rebate/value-based contracting pressure is plausible but unproven in the sources provided.\",\"PCSK9 inhibitor access management is the best broad analog for chronic high-cost pharmacy access, but it is only a qualified comparator.\",\"MA access should be handled separately from commercial coverage because statutory constraints override normal payer preference.\"],\"supplementalMaterial\":{\"originalStructuredBrief\":{\"research_question\":\"How do major US commercial and Medicare Advantage payers currently evaluate and manage coverage for anti-obesity pharmacotherapies, and what evidence, value drivers, and utilization management strategies most influence market access decisions for next-generation GLP-1/GIP therapies?\",\"objective\":\"Assess evolving US payer coverage policies, evidence expectations, reimbursement considerations, and market access barriers for obesity therapies to inform payer engagement strategy, value proposition development, and evidence generation planning ahead of launch.\",\"topic_type\":\"Market access and payer policy research\",\"target_topic\":\"US payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies\",\"target_entities\":[\"Major US commercial payers\",\"Medicare Advantage organizations\",\"PBMs\",\"Regional health plans\",\"Payer medical and pharmacy policy teams\",\"Competitor manufacturers of anti-obesity therapies\"],\"geographies\":[\"United States\"],\"time_horizon\":\"Current state with emphasis on changes in the last 12-18 months\",\"decision_context\":\"Support launch readiness and market access planning for next-generation GLP-1/GIP anti-obesity therapies by identifying payer coverage criteria, evidence thresholds, utilization management practices, and contracting/value arguments likely to shape reimbursement decisions.\",\"priority_dimension\":[\"Coverage policy evolution\",\"Prior authorization and step therapy requirements\",\"Formulary positioning\",\"Evidence expectations for long-term outcomes and cardiovascular benefit\",\"Adherence and persistence expectations\",\"Healthcare cost offset rationale\",\"Emerging outcomes-based contracting models\"],\"output_format\":\"Consulting research brief with payer landscape synthesis, policy trend analysis, and actionable market access implications\",\"depth\":\"High depth; include both published and gray literature sources\",\"audience\":[\"Market access strategy team\",\"Payer engagement team\",\"HEOR team\",\"Commercial leadership\"],\"assumptions\":[\"The request focuses on the US market only.\",\"'Major' payers includes national and large regional commercial payers, PBMs, and Medicare Advantage plans.\",\"Both pharmacy and medical coverage policies may be relevant.\",\"If direct payer evidence is limited, conference insights, advisory boards, and reimbursement trend analyses should be used as supporting sources.\",\"The analysis should preserve ambiguity where payer policies differ materially by plan and geography.\",\"Next-generation GLP-1/GIP therapies are assumed to include emerging obesity agents in this class, without naming a specific product unless evidence requires it.\"]}}}}",
  "providerResponseId": "resp_013c9035f67f4391006a04e0cd3d1c819385879ae54b0f62e5"
}